SCHEMBL339065

SCHEMBL339065

C[N+](C)(C)CCOS(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 6/20 0.44
CHRM1 P11229 6/20 0.44
CHRM3 P20309 6/20 0.44
CHRM2 P08172 5/20 0.44
CHRM4 P08173 5/20 0.44
CHRNB2 P17787 4/20 0.44
CHRNA4 P43681 4/20 0.44
CHRNA7 P36544 3/20 0.44
HTR1A P08908 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ADRA2A P08913 1/20 0.44
ADRA1A P35348 1/20 0.44
PGR P06401 1/20 0.44
TBXA2R P21731 1/20 0.44
CHRNB4 P30926 1/20 0.44
CHRNA3 P32297 1/20 0.44
CHRNA10 Q9GZZ6 1/20 0.44
CHRNA9 Q9UGM1 1/20 0.44
CYP2C19 P33261 2/20 0.43
LMNA P02545 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28176595 0.98 CHRM5 (0.43) CHRM5CHRM1CHRM3CHRM2CHRM4
Glycerin SCHEMBL9060924 0.86 SMN1; SMN2 (0.45) CHRM5CHRM1CHRM3CHRM2CHRM4
SCHEMBL31594744 0.85 FNTA (0.33) CHRM5CHRM1CHRM3CHRM2CHRM4
SCHEMBL868979 0.83 CHRM5 (0.43) CHRM5CHRM1CHRM3CHRM2CHRM4
SCHEMBL28031252 0.79 CHRM5 (0.42) CHRM5CHRM1CHRM3CHRM2CHRM4
Levocarnitine SCHEMBL29564168 0.79 MAPT (0.58) CHRM5CHRM1CHRM3CHRM2CHRM4
SCHEMBL26622389 0.78 CHRNB2 (0.36) CHRM1CHRM3CHRM2CHRNB2CHRNA4
SCHEMBL29199666 0.78 CHRM5 (0.39) CHRM5CHRM1CHRM3CHRM2CHRM4
SCHEMBL13023551 0.78 BBOX1 (0.38) BBOX1
SCHEMBL15527811 0.77 TSHR (0.55) CHRM5CHRM1CHRM3CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES ENTEGRIS INC (US) 2026-01-15 US claimed
WO-2025132928-A1 PROCESS FOR LIGHTENING KERATIN FIBERS USING A PEROXYGENATED SALT, AN OSMOLYTE AND A HYDROXYLATED POLYCARBOXYLIC ACID L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129289-A1 METHODS FOR TREATING KERATIN FIBERS IN A LIGHTENING PROCESS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129288-A1 COMPOSITIONS AND METHODS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129287-A1 METHODS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129283-A1 METHODS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129301-A1 METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129291-A1 METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACID AND AMINO ACIDS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129282-A1 COMPOSITIONS WITH AMINO ACIDS, OSMOLYTES AND CARBOXYLIC ACIDS AND METHODS FOR TREATING KERATIN FIBERS L'OREAL (FR) 2025-06-26 WO claimed
WO-2025129303-A1 METHODS FOR TREATING KERATIN FIBERS WITH OSMOLYTES, CARBOXYLIC ACIDS AND AMINO ACIDS L'OREAL (FR) 2025-06-26 WO claimed
US-5807594-A PROTECTIVE COATING INCREASES STABILITY DUCOA, L.P. (US) 1998-09-15 US claimed
WO-1998037774-A1 FEEDSTUFF ADDITIVE AND METHOD FOR ENHANCING FEED EFFICIENCY IN RUMINANTS DUCOA L.P. (US) 1998-09-03 WO claimed
US-5635458-A CONTAINING LOW MOLECULAR WEIGHT GLYCOL, CHOLINE SALT, FILTRATION CONTROL AGENT AND VISCOSIFIER M-I DRILLING FLUIDS, L.L.C. (US) 1997-06-03 US claimed
EP-0730018-A1 Improved water-based drilling fluids for reduction of water adsorption and hydration of argillaceous rocks M-I Drilling Fluids L.L.C. (US) 1996-09-04 EP claimed
CN-1081569-A agricultural composition for promoting plant photosynthesis SWALLOW ENTERPRISES CO (HK) 1994-02-09 CN claimed
EP-0528834-A4 ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES FROM PHOSPHOLIPIDS 1993-06-02 EP claimed
US-5209858-A By adding an unsubstituted hydroxylamine salt to its solution E. I. DU PONT DE NEMOURS AND COMPANY (US) 1993-05-11 US claimed
EP-0528834-A1 ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES FROM PHOSPHOLIPIDS. LIPOSOME CO INC (US) 1993-03-03 EP claimed
US-5188951-A Reacting phospholipid with primary alcohol in presence of enzyme catalyst in divalent cationic solution to form divalent salt, reacting formed salt with monovalent cationic salt to form monovalent salt THE LIPOSOME COMPANY, INC. (US) 1993-02-23 US claimed
WO-1991016444-A1 ENZYMATIC SYNTHESIS OF SOLUBLE PHOSPHATIDES FROM PHOSPHOLIPIDS THE LIPOSOME COMPANY, INC. (US) 1991-10-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015560-A1 COMPOSITIONS FOR POST-CMP CLEANING OF MICROELECTRONIC DEVICES TET2, ASIC1, PIEZO1 CHRM5 61/4885CHRM1 71/4885CHRM3 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.